Biotech Drug Report Generated Nov 5, 2026

Xaluritamig

AMGN·Amgen

NEUTRAL

Drug Impact Rating3/10

Trial Phase: Phase 3
Time to Market: At least 4-5 years away. The Phase 3 trials (XALience and XALute) are still recruiting with estimated primary completion around 2030, followed by regulatory filing and review.
Why 3/10: No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The two Phase 3 trials (XALience and XALute) are still recruiting with primary completion estimated around 2030. Xaluritamig is one of many pipeline assets at a large-cap biotech, so even a positive data readout would have a modest impact on Amgen's stock.

Actionable Insight NEUTRAL

Xaluritamig has no near-term binary catalyst. The two Phase 3 trials (XALience and XALute) are still recruiting with primary completion estimated around 2030. Watch for future Phase 1/2 data updates at medical conferences (ASCO, ESMO) and any signals on enrollment pace or early efficacy from the ongoing Phase 3 programs. For Amgen, this is one of many pipeline assets; the stock's near-term drivers are broader commercial performance and other pipeline readouts.

Price Chart

Loading chart...

Executive Summary

Xaluritamig (AMG-509) is Amgen's investigational bispecific T-cell engager targeting STEAP1 on prostate cancer cells and CD3 on T-cells. Phase 1 data published in Cancer Discovery (2024) showed encouraging efficacy in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC): a 49% PSA50 response rate and 24% objective response rate across all doses, rising to 59% and 41% respectively at target doses. The drug is now in two Phase 3 trials (XALience in chemo-naive mCRPC, XALute in post-taxane mCRPC) and a Phase 1b in Ewing sarcoma, all still recruiting. For Amgen (AMGN), a $200B+ market-cap biotech, xaluritamig is one of many pipeline assets with no near-term binary catalyst; the Phase 3 primary completion is estimated around 2030.

How It Works

Xaluritamig is a bispecific antibody (a type of immunotherapy) that works like a bridge. One end grabs onto a protein called STEAP1 found on the surface of prostate cancer cells, and the other end grabs onto CD3 on immune T-cells. This brings the T-cells close to the cancer cells, activating them to kill the STEAP1-expressing tumor cells. It is designed using Xencor's XmAb 2+1 technology, which gives it two binding sites for STEAP1 and one for CD3, plus an engineered tail that extends its time in the body.

Trial Status

Two Phase 3 trials are actively recruiting: XALience (NCT07213674) evaluating xaluritamig plus abiraterone vs investigator's choice in chemotherapy-naive mCRPC, and XALute (NCT06691984) evaluating xaluritamig vs cabazitaxel or second ARDT in post-taxane mCRPC. A Phase 1b trial (NCT07297979) in relapsed/refractory Ewing sarcoma began enrolling in April 2026. Phase 1 dose exploration results were published in Cancer Discovery (January 2024) and dose expansion data were presented at ESMO 2024.

The Two-Sided Case

▲ Bull Case4

Phase 1 dose exploration results were encouraging: 49% PSA50 response rate and 24% objective response rate across all doses, rising to 59% PSA50 and 41% ORR at target doses >=0.75 mg in heavily pretreated mCRPC patients.

Xaluritamig is the first STEAP1-targeted T-cell engager in clinical development, targeting a novel antigen highly expressed in prostate cancer with low normal tissue expression, offering a potentially differentiated mechanism.

Two Phase 3 trials are actively recruiting (XALience in chemo-naive mCRPC and XALute in post-taxane mCRPC), plus a Phase 1b in Ewing sarcoma, expanding the addressable patient population.

The drug uses Xencor's XmAb 2+1 bispecific platform with an engineered Fc domain for extended half-life, a design that may offer best-in-class potential among solid tumor T-cell engagers.

▼ Bear Case4

Phase 3 trials (XALience, XALute) are still recruiting with primary completion estimated at 2030, meaning no near-term approval or pivotal data catalyst for years.

Cytokine release syndrome (CRS) was the most common adverse event in Phase 1, primarily during cycle 1, which is a known class effect for T-cell engagers and could limit tolerability in broader populations.

As a single asset within Amgen's massive pipeline, xaluritamig's success or failure has limited impact on the stock price; Amgen's market cap is over $200 billion and the stock is driven by many approved products.

The mean analyst price target for AMGN is ~$404, implying ~15.5% downside from the current ~$478 price, suggesting the broader stock may be fully valued.

Upcoming Catalysts

Potential future data updates from ongoing Phase 1/2 studies at medical conferences (ASCO, ESMO)
Enrollment updates for Phase 3 XALience and XALute trials
Phase 1b Ewing sarcoma interim safety/efficacy data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Amgen PRESS-RELEASE AMGN ·Originating report

Sources · 14

Hover a chip for the title

1 adis.springer.com2 aacrjournals.org3 ascopubs.org4 clinicaltrials.gov5 clinicaltrials.gov6 clinicaltrials.gov7 go.drugbank.com8 droracle.ai9 urotoday.com10 amgen.com11 pubmed.ncbi.nlm.nih.gov12 aacrjournals.org13 prnewswire.com14 pharmaceutical-technology.com